Category Archives: Angelos Stergiou

Angelos Stergiou Notes Benefits of Galinpepimut-S Following Autotransplantation

SELLAS Life Sciences Group’s Phase II clinical trials of galinpepimut-S, an immunotherapeutic anti-cancer treatment, have illustrated significant benefits for those patients who have utilized it following autotransplantation with high-risk multiple myeloma, particularly those with an adverse cytogenetic profile.  “We are … Continue reading

Posted in Angelos Stergiou | Tagged , , | Leave a comment

Angelos Stergiou’s SELLAS has Licensing Agreement with Memorial Sloan Kettering

SELLAS’ immunotherapeutic galinpepimut-S is a late stage WT1 targeted agent licensed from Memorial Sloan Kettering Cancer Center which is undergoing research in treating multiple types of tumors. SELLAS Life Sciences Group’s Phase II study of its galinpepimut-S immunotherapeutic in Multiple … Continue reading

Posted in Angelos Stergiou | Leave a comment

Angelos Stergiou Thrilled With Phase II Trial Results

Dr. Angelos Stergiou values SELLAS’ appointment of Dr. Jonathan Eckard to its executive team in light of Eckard’s experience as Director and Senior Biotechnology Analyst for Barclays, a universal bank with operations in over 50 countries and territories and 48 … Continue reading

Posted in Angelos Stergiou | Tagged , , , | Leave a comment

Angelos Stergiou Announces Dr. Jonathan Eckard Appointment

SELLAS Life Sciences Group specializes in biopharmaceuticals for late stage cancer immunotherapies which cover a significant range of indication for cancer.  SELLAS recently appointed Dr. Jonathan Eckard to their team as a Chief Business and Strategy Officer.  Dr. Eckard has … Continue reading

Posted in Angelos Stergiou | Tagged , , , | Leave a comment

Dr. Angelos Stergiou: Traits of an Ideal Physician

Dr. Angelos M. Stergiou, MD is an entrepreneurial scientist and physician who founded SELLAS Life Sciences Group in 2012. He is now pioneering cancer vaccination research and working on a promising drug, known as the WT1 cancer vaccine (galinpepimut-S), that … Continue reading

Posted in Angelos Stergiou | Tagged | Leave a comment

Dr. Angelos Stergiou: What Does the SELLAS Life Sciences Group Do?

Dr. Angelos M. Stergiou, MD, ScD h.c. founded SELLAS Life Sciences Group with Dr. Miltos K. Sugiultzoglu, a friend and colleague. Through the company, the two have pioneered the cancer vaccine industry with a strong team behind them and promising … Continue reading

Posted in Angelos Stergiou | Tagged | Leave a comment

Dr. Angelos Stergiou: Top Reasons to Study Medicine

Dr. Angelos M. Stergiou, MD, ScD h.c. is a physician, scientist, entrepreneur, inventor and the Vice Chairman and CEO of SELLAS Life Sciences Group. He is presently working on a number of novel products through his company, the most notable … Continue reading

Posted in Angelos Stergiou | Leave a comment